Oncolytic herpes viruses have show promise for the treatment of cancer however it is unlikely that the optimal application of these viruses will be as single therapeutic agents. An alternative strategy would be to utilise these viruses to deliver therapeutic transgenes and enhance their tumour cell killing capacity.
|Number of pages||2|
|Publication status||Published - 2012|
|Event||34th Annual Meeting of the United Kingdom Environmental Mutagen Society - Nottingham, United Kingdom|
Duration: 29 Jun 2011 → 1 Jul 2011
- cancer therapy
- gene transfer
Sorensen, A., Mairs, R. J., Braidwood, L., Joyce, C., Conner, J., Pimlott, S., ... Boyd, M. (2012). Efficacy in vivo of a cancer therapy strategy combining HSV1716 mediated oncolysis with gene transfer and targeted radiotherapy. Mutagenesis, 27(1), 134-135. https://doi.org/10.1093/mutage/ger068